Disease steps in multiple sclerosis: A simple approach to evaluate disease progression

Neurology

Volumn 45, Issue 2, 1995, Pages 251-255

  Hohol, Marika J ^a   Orav, E J ^b   Weiner, H L ^a  

^a Boston University Medical Campus   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DETERIORATION; DISABILITY; FEMALE; GAIT DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS;

DISABLED PERSONS; GAIT; HUMAN; LOCOMOTION; MULTIPLE SCLEROSIS; REPRODUCIBILITY OF RESULTS; WHEELCHAIRS;

EID: 0028817189     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.45.2.251     Document Type: Article

References (18)

1. The IFNB Multiple Sclerosis Study Group. Interferon betalb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
3. Francis DA, Bain P, Swan AV, et al. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 1991;48:299-301.
4. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992;42:859-863.
5. Mumford CJ, Compston A. Problems with rating scales for multiple sclerosis: a novel approach—the CAMBS score. J Neurol 1993;240:209-215.
6. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC Canadian Cooperative MS Study Group. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990;40:971-975.
7. Pia Amato M, Fratiglioni L, Groppi C, et al. Interrater reliability in assessing Functional Systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol 1988;45:746-748.
8. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988;38:1793-1798.
9. Alexander L. New concept of critical steps in course of chronic debilitating neurologic disease in evaluation of therapeutic response. Arch Neurol Psychiat 1951;66:253-271.
10. Fog T. A scoring system for neurological impairment in multiple sclerosis. Acta Neurol Scand 1965;31(suppl 13):551-555.
11. Mickey MR, Ellison GW, Myers LW. An illness severity score for multiple sclerosis. Neurology 1984;34:1343-1347.
12. Pedersen E. A rating system for neurological impairment in multiple sclerosis. Acta Neurol Scand 1965;31(suppl 13):557-558.
13. Sipe JC, Knobler RL, Braheny SL, Rice GPA, Panitch HS, Oldstone MBA. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-1372.
14. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
15. Cook SD, Devereux C, Troiano R, et al. Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neurol 1987;22:634-638.
16. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-1769.
17. Rosner B. Fundamentals of biostatistics. Boston: PWS-Kent, 1990:458.
18. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46:1107-1112.